Open label naturalistic six month study of aripiprazole in schizophrenia measuring functional outcomes and positive, negative and cognitive symptoms

Trial Profile

Open label naturalistic six month study of aripiprazole in schizophrenia measuring functional outcomes and positive, negative and cognitive symptoms

Completed
Phase of Trial: Phase II

Latest Information Update: 21 Jun 2016

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Psychotic disorders; Schizophrenia
  • Focus Therapeutic Use
  • Acronyms Double A Study
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 08 Jun 2016 Status changed from recruiting to completed.
    • 30 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top